Likewise, immune profiling of PM underscored the mesenchymal subtype with a considerable expression of TGF‐β, thereby raising the question of whether targeting the TGF‐β pathway in PME may restore anti‐tumour immunity and better manage GCPM. Here, TGFB1 is linked to neoplasm.